Outcome of Meeting of Board of Directors held today i.e. Monday, April 28, 2025, in terms of Regulation 30 of SEBI (LODR) Regulations, 2015, for Consideration and approval of Audited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts more than Nifty Microcap 250 and 4.9 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Global Longlife Hospital and Research Ltd approved the audited financial results for the half-year and full year ended March 31, 2025, with statutory auditor M/s. R B Gohil & Co. issuing an unmodified (clean) opinion. Revenue from operations collapsed to just ₹57.73 lakhs in FY25 from ₹1,351.45 lakhs in FY24, a decline of about 96%. The company swung to a net profit of ₹19.87 lakhs (vs a loss of ₹218.81 lakhs last year), but this was entirely driven by other income of ₹501.61 lakhs, mainly gains from sale of fixed assets (₹2,117.23 lakhs) and mutual fund redemptions. Core hospital operations are nearly non-existent. The company has fully deleveraged, repaying all long-term (₹340.97 lakhs) and short-term borrowings (₹932.71 lakhs), and cash on hand jumped to ₹2,149.18 lakhs from ₹38.54 lakhs.
While the headline return to profit looks positive, it is entirely driven by one-time asset sales rather than operational performance — core hospital business has almost completely wound down. The substantial cash pile and zero debt may support future business plans or a relaunch, but shareholders should note that ongoing operations are minimal, making future revenue sustainability questionable.